CELG:NGS-Celgene Corporation

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing Price

USD 89.27

Change

-3.44 (-3.71)%

Market Cap

USD 62.79B

Volume

6.70M

Yahoo Analyst Target

USD 112.73 (26.28%)

STA Analyst Target

USD 113.32 (26.94%)
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

About

Celgene Corp is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2018-08-15 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
AMGN Amgen Inc.

-0.50 (-0.26%)

USD 126.39B
GILD Gilead Sciences Inc.

-2.47 (-3.19%)

USD 97.02B
BIIB Biogen Inc.

-2.91 (-0.85%)

USD 68.64B
SHPG Shire plc

-0.80 (-0.47%)

USD 51.31B
VRTX Vertex Pharmaceuticals Incorpo..

-2.93 (-1.67%)

USD 44.21B
REGN Regeneron Pharmaceuticals Inc.

-4.36 (-1.19%)

USD 39.10B
ALXN Alexion Pharmaceuticals Inc.

-4.36 (-3.64%)

USD 25.70B
BMRN BioMarin Pharmaceutical Inc.

-1.33 (-1.29%)

USD 18.08B
INCY Incyte Corporation

+0.42 (+0.63%)

USD 14.22B
GRFS Grifols S.A.

-0.71 (-3.43%)

USD 13.66B

ETFs Containing CELG

IBB iShares Nasdaq Biotechnol.. 7.91 % 0.47 %

-1.83 (-1.56%)

USD 9.18B
BIB ProShares Ultra Nasdaq Bi.. 6.43 % 0.95 %

-2.33 (-3.59%)

USD 0.34B
BBH VanEck Vectors Biotech ET.. 5.84 % 0.35 %

-1.92 (-1.48%)

USD 0.45B
UBIO Proshares UltraPro Nasdaq.. 5.82 % 0.95 %

-2.02 (-5.08%)

USD 0.03B
HHL:CA Harvest Healthcare Leader.. 4.98 % 1.24 %

-0.03 (-0.35%)

CAD 0.28B
FMDG Fieldstone Merlin Dynamic.. 3.95 % 0.00 %

N/A

N/A
FBT First Trust Amex Biotech .. 3.59 % 0.56 %

-2.89 (-1.91%)

USD 2.13B
ARKG ARK Genomic Revolution Mu.. 3.58 % 0.75 %

-0.37 (-1.19%)

USD 0.02B
LNGR Global X Longevity Themat.. 2.79 % 0.52 %

-0.37 (-1.75%)

N/A
BBP Virtus LifeSci Biotech Pr.. 2.67 % 0.84 %

-0.81 (-1.86%)

USD 0.03B
QQXT First Trust NASDAQ-100 Ex.. 1.79 % 0.60 %

-0.74 (-1.42%)

USD 0.09B
RYH Invesco S&P 500 Equal Wei.. 1.74 % 0.40 %

-1.33 (-0.68%)

USD 0.66B
XBI SPDR Series Trust S&P Bio.. 1.51 % 0.35 %

-1.81 (-1.91%)

USD 5.28B
QQEW First Trust NASDAQ-100 Eq.. 1.16 % 0.60 %

-0.79 (-1.26%)

USD 0.57B
OEW Invesco S&P 100 Equal Wei.. 1.12 % 0.40 %

N/A

USD 3.39M
CHGX Change Finance U.S. Large.. 1.10 % 0.00 %

N/A

USD 3.99M
QQQE Direxion NASDAQ-100 Equal.. 1.05 % 0.35 %

-0.62 (-1.33%)

USD 0.19B
ERM EquityCompass Risk Manage.. 0.74 % 0.65 %

-0.21 (-0.92%)

USD 0.03B
TERM EquityCompass Tactical Ri.. 0.74 % 0.65 %

-0.13 (-0.59%)

USD 0.06B
FWDD Madrona Domestic 0.58 % 1.25 %

-0.14 (-0.25%)

USD 0.03B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -14.46% 48% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -14.46% 47% F 24% F
Trailing 12 Months  
Capital Gain -32.05% 31% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -32.05% 31% F 13% F
Trailing 5 Years  
Capital Gain 33.73% 63% D 47% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 33.73% 61% D- 43% F
Average Annual (5 Year Horizon)  
Capital Gain 9.84% 55% F 57% F
Dividend Return 9.84% 55% F 53% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 27.40% 80% B- 49% F
Risk Adjusted Return 35.90% 69% D+ 48% F
Market Capitalization 93.78B 99% A+ 99% A+

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
(Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 24.46 4% F 23% F
Price/Book Ratio 9.45 18% F 11% F
Price / Cash Flow Ratio 4.45 7% F 25% F
Price/Free Cash Flow Ratio 18.44 5% F 28% F
Management Effectiveness  
Return on Equity 37.04% 89% B+ 92% A-
Return on Invested Capital 10.52% 87% B+ 71% C-
Return on Assets 8.88% 94% A 87% B+
Debt to Equity Ratio 233.75% 7% F 8% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

CELG:NGS-Celgene Corporation

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing Price

USD 89.27

Change

-3.44 (-3.71)%

Market Cap

USD 62.79B

Volume

6.70M

Yahoo Analyst Target

USD 112.73 (26.28%)

STA Analyst Target

USD 113.32 (26.94%)
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

Values as of: 2018-08-15